These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27156525)

  • 1. [Meta-analysis of the side-effect profiles of modern radiation therapies for patients with prostate cancer].
    Zemplényi AT; Mangel L; Kaló Z; Endrei D; Lohner S; Boncz I
    Orv Hetil; 2016 May; 157(20):776-88. PubMed ID: 27156525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
    Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
    Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts.
    Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer.
    Sharma NK; Li T; Chen DY; Pollack A; Horwitz EM; Buyyounouski MK
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):437-44. PubMed ID: 21050673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
    Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
    Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
    Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer.
    Sujenthiran A; Nossiter J; Charman SC; Parry M; Dasgupta P; van der Meulen J; Cathcart PJ; Clarke NW; Payne H; Aggarwal A
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1253-1260. PubMed ID: 28974414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer.
    Arcangeli G; Fowler J; Gomellini S; Arcangeli S; Saracino B; Petrongari MG; Benassi M; Strigari L
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1013-21. PubMed ID: 20447774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer.
    Alongi F; Cozzi L; Fogliata A; Iftode C; Comito T; Clivio A; Villa E; Lobefalo F; Navarria P; Reggiori G; Mancosu P; Clerici E; Tomatis S; Taverna G; Graziotti P; Scorsetti M
    Anticancer Res; 2013 Oct; 33(10):4537-43. PubMed ID: 24123027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up.
    Hou Z; Li G; Bai S
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1063-71. PubMed ID: 25173623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rectal/urinary toxicity after hypofractionated vs. conventional radiotherapy in high risk prostate cancer: systematic review and meta analysis.
    Di Franco R; Borzillo V; Ravo V; Ametrano G; Cammarota F; Rossetti S; Romano FJ; D'Aniello C; Cavaliere C; Iovane G; Porricelli MA; Muto M; Berretta M; Facchini G; Muto P
    Eur Rev Med Pharmacol Sci; 2017 Aug; 21(16):3563-3575. PubMed ID: 28925488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
    Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate hypofractionated radiation therapy with injection of hyaluronic acid: acute toxicities in a phase 2 study.
    Chapet O; Decullier E; Bin S; Faix A; Ruffion A; Jalade P; Fenoglietto P; Udrescu C; Enachescu C; Azria D
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):730-6. PubMed ID: 25752385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.
    Kalakota K; Liauw SL
    Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.
    Di Franco R; Borzillo V; Ravo V; Ametrano G; Falivene S; Cammarota F; Rossetti S; Romano FJ; D'Aniello C; Cavaliere C; Iovane G; Piscitelli R; Berretta M; Muto P; Facchini G
    Oncotarget; 2017 Mar; 8(10):17383-17395. PubMed ID: 28129649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.